Lansing-based Ionetix has acquired a 10,300-square-foot facility in Lansing for its new Targeted Alpha Radionuclide Manufacturing Center. The company will equip the site for drug manufacturing capabilities, pre-clinical research, drug development, and early-stage clinical trials.
Ionetix is a cyclotron (a device that accelerates charged atoms and subatomic particles – protons, neutrons, and electrons) technology, and isotope (forms of elements that have different masses on the atomic level and may therefore be radioactive) company.
Targeted Radionuclide Therapy, which the company’s work advances, is an emerging cancer treatment that is well-suited to treating metastatic cancer, or cancer that has spread from its original tumor site. Using molecules such as antibodies, peptides, and others that target specific receptors, therapeutic alpha radionuclides are delivered directly to cancer cells, causing cancer cell death while preserving the surrounding healthy tissue.
“Targeted Alpha Therapy has the potential to be a life-changing and life-saving cancer treatment option to which Ionetix can make great contributions,” says Kevin Cameron, CEO. “Using our proprietary cyclotron technology and distribution network, Ionetix is positioned to deliver alpha radionuclide therapeutics that would otherwise not be possible.”
The new center is slated to open in early 2022 and will create more than 30 skilled jobs in the Lansing area once fully operational. Ionetix was founded in 2009.